Lupin Limited launched Formoflo-G MDI, the world's first fixed-dose triple combination metered-dose inhaler for chronic obstructive pulmonary disease (COPD) management in India. The product received approval from the Drug Controller General of India (DCGI), offering a new treatment option for moderate to severe cases.

The launch addresses a significant public health challenge, as more than 55 million people in India live with COPD. It remains a leading cause of death and disability in the country. Formoflo-G combines three established therapies: Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate. This single-strength, twice-daily formulation simplifies long-term management for patients.

Strategic positioning in respiratory care

Lupin ranks second in the Indian respiratory therapy segment, according to IQVIA data for the moving annual total (MAT) ending March 2026. The introduction of Formoflo-G reinforces this leadership position by expanding the company's portfolio with a differentiated therapy.

Nilesh Gupta, Managing Director of Lupin, stated that the launch reflects the company's commitment to addressing unmet patient needs through high-quality therapies. He emphasized the goal of improving outcomes for respiratory disease patients by combining innovation with accessibility.

Rajeev Sibal, President of India Region Formulations at Lupin, noted that the product strengthens the company's respiratory portfolio. He highlighted that it provides healthcare professionals with an important treatment option for appropriate COPD patients.

Product specifications and market context

The new inhaler is designed for the long-term management and treatment of moderate to severe COPD. By integrating three active ingredients into one device, it aims to enhance patient compliance and therapeutic efficacy.

Lupin operates as a global pharmaceutical leader headquartered in Mumbai, with products distributed in over 100 markets. The company maintains strong leadership in the US and India across core therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women's health. Its infrastructure includes 15 manufacturing facilities and six research centers supporting a workforce of over 26,000 professionals.

Lupin Limited announced that its step-down subsidiary, Multicare Pharmaceuticals Philippines, Inc. (MPPI), has completed the buyback of 30,559 shares. Consequently, effective October 1, 2026, MPPI has become a wholly owned subsidiary of Nanomi B.V., the Netherlands.

Nanomi B.V. is a wholly owned subsidiary of Lupin Limited. The completion of this transaction follows an earlier intimation provided to stock exchanges on July 1, 2026, regarding the ongoing process of acquiring the balance shares held by minority shareholders.

Regulatory Disclosure Details

The company filed this disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that the acquisition of the remaining equity stake transforms MPPI's status within the corporate structure.

Corporate Structure Implications

The move simplifies the ownership structure of the Philippine operations. By eliminating minority interests, Lupin consolidates full control over MPPI through its Dutch subsidiary, Nanomi B.V. This structural change does not involve any external capital infusion or debt restructuring as per the disclosure.

The buyback was executed by MPPI itself, targeting the specific block of 30,559 shares that remained outside the group's control. With this transaction closed, there are no remaining external shareholders in Multicare Pharmaceuticals Philippines, Inc.